Summary

Global Drug Discovery Outsourcing Market 2024-2028
The drug discovery outsourcing market is forecasted to grow by USD 1.79 bn during 2023-2028, accelerating at a CAGR of 7.44% during the forecast period. The report on the drug discovery outsourcing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by robust demand for biosimilars, prioritization of core competencies, and an increased number of FDA-approved manufacturing facilities in developing nations.
Technavio's drug discovery outsourcing market is segmented as below:
By Product
• Small-molecules
• Biologics
By End-user
• Big pharmaceutical companies
• Small and medium-sized pharmaceutical companies
• Generic pharmaceutical companies
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the technological advancements boosting drug discovery outsourcing as one of the prime reasons driving the drug discovery outsourcing market growth during the next few years. Also, increased demand for regenerative medicine and cost reduction and efficiency-boosting demand for drug discovery outsourcing will lead to sizable demand in the market.
The report on the drug discovery outsourcing market covers the following areas:
• Drug discovery outsourcing market sizing
• Drug discovery outsourcing market forecast
• Drug discovery outsourcing market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading drug discovery outsourcing market vendors that include Aragen Life Sciences Pvt. Ltd., Aurigene Discovery Technologies, Catalent Inc., Charles River Laboratories International Inc., Curia Global Inc., Domainex, Eurofins Scientific SE, Evotec SE, GenScript Biotech Corp., LABORATORY CORPORATION OF AMERICA HOLDINGS, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, Oncodesign Services, PerkinElmer Inc, QIAGEN NV, Shanghai Medicilon Inc., Syngene International Ltd., Thermo Fisher Scientific Inc., and WuXi AppTec Co. Ltd. Also, the drug discovery outsourcing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/drug-discovery-outsourcing-market-industry-analysis
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

ページTOPに戻る

Table of Contents

- 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Global Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
o Exhibit 06: Executive Summary - Chart on Market Segmentation by End-user
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
- 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
- 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
- 4 Historic Market Size
o 4.1 Global drug discovery outsourcing market 2018 - 2022
o Exhibit 18: Historic Market Size - Data Table on global drug discovery outsourcing market 2018 - 2022 ($ billion)
o 4.2 Product Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
o 4.3 End-user Segment Analysis 2018 - 2022
o Exhibit 20: Historic Market Size - End-user Segment 2018 - 2022 ($ billion)
o 4.4 Geography Segment Analysis 2018 - 2022
o Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
o 4.5 Country Segment Analysis 2018 - 2022
o Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
- 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
- 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 30: Chart on Product - Market share 2023-2028 (%)
o Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
o 6.2 Comparison by Product
o Exhibit 32: Chart on Comparison by Product
o Exhibit 33: Data Table on Comparison by Product
o 6.3 Small-molecules - Market size and forecast 2023-2028
o Exhibit 34: Chart on Small-molecules - Market size and forecast 2023-2028 ($ billion)
o Exhibit 35: Data Table on Small-molecules - Market size and forecast 2023-2028 ($ billion)
o Exhibit 36: Chart on Small-molecules - Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Small-molecules - Year-over-year growth 2023-2028 (%)
o 6.4 Biologics - Market size and forecast 2023-2028
o Exhibit 38: Chart on Biologics - Market size and forecast 2023-2028 ($ billion)
o Exhibit 39: Data Table on Biologics - Market size and forecast 2023-2028 ($ billion)
o Exhibit 40: Chart on Biologics - Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Product
o Exhibit 42: Market opportunity by Product ($ billion)
o Exhibit 43: Data Table on Market opportunity by Product ($ billion)
- 7 Market Segmentation by End-user
o 7.1 Market segments
o Exhibit 44: Chart on End-user - Market share 2023-2028 (%)
o Exhibit 45: Data Table on End-user - Market share 2023-2028 (%)
o 7.2 Comparison by End-user
o Exhibit 46: Chart on Comparison by End-user
o Exhibit 47: Data Table on Comparison by End-user
o 7.3 Big pharmaceutical companies - Market size and forecast 2023-2028
o Exhibit 48: Chart on Big pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
o Exhibit 49: Data Table on Big pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
o Exhibit 50: Chart on Big pharmaceutical companies - Year-over-year growth 2023-2028 (%)
o Exhibit 51: Data Table on Big pharmaceutical companies - Year-over-year growth 2023-2028 (%)
o 7.4 Small and medium-sized pharmaceutical companies - Market size and forecast 2023-2028
o Exhibit 52: Chart on Small and medium-sized pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
o Exhibit 53: Data Table on Small and medium-sized pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
o Exhibit 54: Chart on Small and medium-sized pharmaceutical companies - Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Small and medium-sized pharmaceutical companies - Year-over-year growth 2023-2028 (%)
o 7.5 Generic pharmaceutical companies - Market size and forecast 2023-2028
o Exhibit 56: Chart on Generic pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
o Exhibit 57: Data Table on Generic pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
o Exhibit 58: Chart on Generic pharmaceutical companies - Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Generic pharmaceutical companies - Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by End-user
o Exhibit 60: Market opportunity by End-user ($ billion)
o Exhibit 61: Data Table on Market opportunity by End-user ($ billion)
- 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America - Market size and forecast 2023-2028
o Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
o Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
o 9.4 Europe - Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
o Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
o 9.5 Asia - Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
o Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
o Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
o 9.7 US - Market size and forecast 2023-2028
o Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
o Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
o 9.8 UK - Market size and forecast 2023-2028
o Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
o Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)
o 9.9 Germany - Market size and forecast 2023-2028
o Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
o Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
o 9.10 Canada - Market size and forecast 2023-2028
o Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
o Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
o Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
o 9.11 Japan - Market size and forecast 2023-2028
o Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
o Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
o Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ billion)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ billion)
- 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
- 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
- 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Aragen Life Sciences Pvt. Ltd.
o Exhibit 111: Aragen Life Sciences Pvt. Ltd. - Overview
o Exhibit 112: Aragen Life Sciences Pvt. Ltd. - Product / Service
o Exhibit 113: Aragen Life Sciences Pvt. Ltd. - Key offerings
o 12.4 Catalent Inc.
o Exhibit 114: Catalent Inc. - Overview
o Exhibit 115: Catalent Inc. - Business segments
o Exhibit 116: Catalent Inc. - Key offerings
o Exhibit 117: Catalent Inc. - Segment focus
o 12.5 Charles River Laboratories International Inc.
o Exhibit 118: Charles River Laboratories International Inc. - Overview
o Exhibit 119: Charles River Laboratories International Inc. - Business segments
o Exhibit 120: Charles River Laboratories International Inc. - Key news
o Exhibit 121: Charles River Laboratories International Inc. - Key offerings
o Exhibit 122: Charles River Laboratories International Inc. - Segment focus
o 12.6 Curia Global Inc.
o Exhibit 123: Curia Global Inc. - Overview
o Exhibit 124: Curia Global Inc. - Product / Service
o Exhibit 125: Curia Global Inc. - Key offerings
o 12.7 Domainex
o Exhibit 126: Domainex - Overview
o Exhibit 127: Domainex - Product / Service
o Exhibit 128: Domainex - Key offerings
o 12.8 Eurofins Scientific SE
o Exhibit 129: Eurofins Scientific SE - Overview
o Exhibit 130: Eurofins Scientific SE - Business segments
o Exhibit 131: Eurofins Scientific SE - Key news
o Exhibit 132: Eurofins Scientific SE - Key offerings
o Exhibit 133: Eurofins Scientific SE - Segment focus
o 12.9 Evotec SE
o Exhibit 134: Evotec SE - Overview
o Exhibit 135: Evotec SE - Business segments
o Exhibit 136: Evotec SE - Key offerings
o Exhibit 137: Evotec SE - Segment focus
o 12.10 GenScript Biotech Corp.
o Exhibit 138: GenScript Biotech Corp. - Overview
o Exhibit 139: GenScript Biotech Corp. - Business segments
o Exhibit 140: GenScript Biotech Corp. - Key offerings
o Exhibit 141: GenScript Biotech Corp. - Segment focus
o 12.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
o Exhibit 142: LABORATORY CORPORATION OF AMERICA HOLDINGS - Overview
o Exhibit 143: LABORATORY CORPORATION OF AMERICA HOLDINGS - Business segments
o Exhibit 144: LABORATORY CORPORATION OF AMERICA HOLDINGS - Key news
o Exhibit 145: LABORATORY CORPORATION OF AMERICA HOLDINGS - Key offerings
o Exhibit 146: LABORATORY CORPORATION OF AMERICA HOLDINGS - Segment focus
o 12.12 Lonza Group Ltd.
o Exhibit 147: Lonza Group Ltd. - Overview
o Exhibit 148: Lonza Group Ltd. - Business segments
o Exhibit 149: Lonza Group Ltd. - Key news
o Exhibit 150: Lonza Group Ltd. - Key offerings
o Exhibit 151: Lonza Group Ltd. - Segment focus
o 12.13 Lupin Ltd.
o Exhibit 152: Lupin Ltd. - Overview
o Exhibit 153: Lupin Ltd. - Product / Service
o Exhibit 154: Lupin Ltd. - Key news
o Exhibit 155: Lupin Ltd. - Key offerings
o 12.14 Oncodesign Services
o Exhibit 156: Oncodesign Services - Overview
o Exhibit 157: Oncodesign Services - Product / Service
o Exhibit 158: Oncodesign Services - Key offerings
o 12.15 PerkinElmer Inc
o Exhibit 159: PerkinElmer Inc - Overview
o Exhibit 160: PerkinElmer Inc - Business segments
o Exhibit 161: PerkinElmer Inc - Key news
o Exhibit 162: PerkinElmer Inc - Key offerings
o Exhibit 163: PerkinElmer Inc - Segment focus
o 12.16 QIAGEN NV
o Exhibit 164: QIAGEN NV - Overview
o Exhibit 165: QIAGEN NV - Product / Service
o Exhibit 166: QIAGEN NV - Key offerings
o 12.17 Thermo Fisher Scientific Inc.
o Exhibit 167: Thermo Fisher Scientific Inc. - Overview
o Exhibit 168: Thermo Fisher Scientific Inc. - Business segments
o Exhibit 169: Thermo Fisher Scientific Inc. - Key news
o Exhibit 170: Thermo Fisher Scientific Inc. - Key offerings
o Exhibit 171: Thermo Fisher Scientific Inc. - Segment focus
- 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 172: Inclusions checklist
o Exhibit 173: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 174: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 175: Research methodology
o Exhibit 176: Validation techniques employed for market sizing
o Exhibit 177: Information sources
o 13.5 List of abbreviations
o Exhibit 178: List of abbreviations